Efficacy and safety of aztreonam versus tobramycin for aerobic gram-negative bacilli lower respiratory tract infections.
Aztreonam therapy was evaluated for the management of 80 patients with gram-negative bacilli lower respiratory tract infections. Study results confirmed its efficacy and safety for this indication.
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001398:Aztreonam; D001424:Bacterial Infections / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006088:Gram-Negative Aerobic Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D011897:Random Allocation; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D014031:Tobramycin / Q000009:adverse effects / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D001398:Aztreonam; D014031:Tobramycin